Next generation pan-cancer blood proteome profiling using proximity extension assay.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
18 07 2023
18 07 2023
Historique:
received:
26
10
2022
accepted:
27
06
2023
medline:
21
7
2023
pubmed:
19
7
2023
entrez:
18
7
2023
Statut:
epublish
Résumé
A comprehensive characterization of blood proteome profiles in cancer patients can contribute to a better understanding of the disease etiology, resulting in earlier diagnosis, risk stratification and better monitoring of the different cancer subtypes. Here, we describe the use of next generation protein profiling to explore the proteome signature in blood across patients representing many of the major cancer types. Plasma profiles of 1463 proteins from more than 1400 cancer patients are measured in minute amounts of blood collected at the time of diagnosis and before treatment. An open access Disease Blood Atlas resource allows the exploration of the individual protein profiles in blood collected from the individual cancer patients. We also present studies in which classification models based on machine learning have been used for the identification of a set of proteins associated with each of the analyzed cancers. The implication for cancer precision medicine of next generation plasma profiling is discussed.
Identifiants
pubmed: 37463882
doi: 10.1038/s41467-023-39765-y
pii: 10.1038/s41467-023-39765-y
pmc: PMC10354027
doi:
Substances chimiques
Proteome
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4308Informations de copyright
© 2023. The Author(s).
Références
Biotechnol Rep (Amst). 2018 Apr 17;18:e00252
pubmed: 29876303
J Immunol. 1972 Jul;109(1):129-35
pubmed: 4113792
Acta Oncol. 2018 Feb;57(2):187-194
pubmed: 28631533
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
J Intern Med. 2015 Dec;278(6):645-59
pubmed: 26096600
Cell. 2018 Apr 5;173(2):283-285
pubmed: 29625045
Nat Biotechnol. 2019 Apr;37(4):367-369
pubmed: 30877282
Medicine (Baltimore). 2021 Apr 2;100(13):e25148
pubmed: 33787596
J Proteome Res. 2022 Sep 2;21(9):2071-2074
pubmed: 36004690
Epidemiology. 2005 Jan;16(1):73-81
pubmed: 15613948
Neurooncol Adv. 2021 Jun 01;3(1):vdab072
pubmed: 34286278
Biotechniques. 2021 Sep;71(3):473-483
pubmed: 34431357
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Nat Rev Cancer. 2015 Dec;15(12):747-56
pubmed: 26536825
Innovation (Camb). 2021 Jul 01;2(3):100141
pubmed: 34557778
Mol Cell Proteomics. 2021;20:100168
pubmed: 34715355
N Biotechnol. 2012 Jun 15;29(5):543-9
pubmed: 22155539
Science. 2022 Mar 18;375(6586):eaay9040
pubmed: 35298272
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nat Commun. 2021 May 3;12(1):2493
pubmed: 33941778
Clin Cancer Res. 2008 Jul 1;14(13):4225-31
pubmed: 18594004
Gastroenterology. 2020 Jan;158(2):418-432
pubmed: 31394083
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
Mol Cell Biochem. 2014 Feb;387(1-2):261-70
pubmed: 24234423
BMJ. 2018 Sep 05;362:k3519
pubmed: 30185521
Nat Med. 2022 Jan;28(1):136-143
pubmed: 35027757
Cancer. 2022 Dec 15;128(24):4251-4284
pubmed: 36301149
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Nat Commun. 2020 Sep 8;11(1):4487
pubmed: 32900998
Nat Commun. 2014 May 29;5:3887
pubmed: 24871328
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
J Proteome Res. 2022 Apr 1;21(4):1204-1207
pubmed: 35119864